First Light Asset Management LLC Trims Stock Position in Repligen Co. (NASDAQ:RGEN)

First Light Asset Management LLC cut its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 50.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 82,455 shares of the biotechnology company's stock after selling 83,418 shares during the quarter. Repligen makes up about 1.1% of First Light Asset Management LLC's holdings, making the stock its 24th biggest position. First Light Asset Management LLC owned approximately 0.15% of Repligen worth $11,869,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. UMB Bank n.a. increased its position in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 110 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in shares of Repligen during the 4th quarter valued at $216,000. Van ECK Associates Corp raised its stake in shares of Repligen by 7.8% during the 4th quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company's stock worth $6,078,000 after purchasing an additional 3,066 shares during the period. Stephens Investment Management Group LLC boosted its holdings in shares of Repligen by 7.4% in the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock worth $77,267,000 after buying an additional 37,057 shares during the last quarter. Finally, Sanctuary Advisors LLC bought a new position in Repligen during the third quarter valued at about $233,000. 97.64% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on RGEN. Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price for the company in a research report on Tuesday. TD Cowen assumed coverage on Repligen in a research report on Monday, February 10th. They issued a "buy" rating and a $200.00 target price for the company. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a research report on Monday. Evercore ISI assumed coverage on Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective for the company. Finally, Canaccord Genuity Group dropped their price objective on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a report on Wednesday, April 16th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, Repligen has a consensus rating of "Moderate Buy" and a consensus price target of $173.25.

Repligen Price Performance

Shares of RGEN traded down $0.79 during mid-day trading on Thursday, reaching $137.20. 481,876 shares of the stock traded hands, compared to its average volume of 718,136. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The company has a market cap of $7.70 billion, a price-to-earnings ratio of -269.02, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The firm has a fifty day moving average price of $138.77 and a 200 day moving average price of $145.87.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. During the same period in the prior year, the company earned $0.28 EPS. The company's quarterly revenue was up 10.4% compared to the same quarter last year. As a group, equities research analysts predict that Repligen Co. will post 1.72 earnings per share for the current year.

Insider Buying and Selling at Repligen

In other Repligen news, Director Margaret Pax acquired 250 shares of the business's stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 1.20% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.